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Abstract
Viruses induce signaling and host defense during infection. Employing these natural trigger mechanisms to combat organ
or tissue failure is hampered by harmful effects of most viruses. Here we demonstrate that SV40 empty capsids (Virus Like
Particles-VLPs), with no DNA, induce host Hsp/c70 and Akt-1 survival pathways, key players in cellular survival mechanisms.
We postulated that this signaling might protect against organ damage in vivo. Acute kidney injury (AKI) was chosen as
target. AKI is critical, prevalent disorder in humans, caused by nephrotoxic agents, sepsis or ischemia, via apoptosis/necrosis
of renal tubular cells, with high morbidity and mortality. Systemic administration of VLPs activated Akt-1 and upregulated
Hsp/c70 in vivo. Experiments in mercury-induced AKI mouse model demonstrated that apoptosis, oxidative stress and toxic
renal failure were significantly attenuated by pretreatment with capsids prior to the mercury insult. Survival rate increased
from 12% to .60%, with wide dose response. This study demonstrates that SV40 VLPs, devoid of DNA, may potentially be
used as prophylactic agent for AKI. We anticipate that these finding may be projected to a wide range of organ failure, using
empty capsids of SV40 as well as other viruses.
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Introduction
Simian virus 40 (SV40) is a non-enveloped primate virus, with a
small, double-stranded, circular DNA genome of 5.2 kb. SV40
infects dividing and non-dividing cells and does not depend on
host cell cycle [1]. This is in contrast to many other viruses that
infect only dividing cells and enter the nucleus during mitosis when
the nuclear envelope is disassembled. This suggests that SV40
activates signaling pathways that permit nuclear entry of the viral
genome. SV40 enters host cells by an atypical, slow endocytic
process mediated by caveolae [2,3] via the endoplasmic reticulum
[4]. This is unlike most viruses, that utilize clathrin-coated and
non-coated vesicles for endocytosis [5]. In a parallel project we
have started a detailed study on cellular signals induced by the
infecting SV40. We have found that SV40 activates Akt-1 survival
pathway and the Hsp/c70 chaperones via PLC-c signaling
(unpublished results), very early post infection. SV40 also
protected CV-1 cells against etoposide-induced apoptosis (our
unpublished results). These findings led us to hypothesize that
cellular uptake of SV40, or the viral capsid alone, might function
in protection against in vivo cellular damage and degenerative
diseases. Because SV40 has a natural affinity to the kidney, we
chose renal failure as a first target for testing the hypothesis.
Acute kidney injury (AKI), previously known as acute tubular
necrosis (ATN), is characterized by abrupt and reversible kidney
dysfunction, caused by sepsis, ischemia or nephrotoxic agents. The
major underlying pathogenic mechanisms are apoptosis and
necrosis of kidney tubular cells [6], in particular in the proximal
convoluted tubuli. Many recent studies suggest that chaperones, in
particular members of the Hsp70 family, may provide protection
against AKI [7] (for recent reviews see [8,9,10]).
Nephrotoxic agents are commonly used in medicine. These
include contrast material that is administered routinely to patients
undergoing radiological procedures, such as computerized tomogra-
phy and cardiac and other angiographies. Contrast media induced
nephropathy is the third most common cause of acute renal failure in
hospitalized patients, and may lead to the development of end stage
acute renal failure in up to 10% of patients with prior renal
dysfunction, and also in patients with prior normal renal function
[11,12]. Furthermore, in patients who develop contrast media
induced nephropathy following coronary interventions, long term
mortality is increased irrespective of the presence of prior renal
dysfunction [13]. In addition, various drugs, in particular anticancer,
antibiotic and immunosuppressant drugs are also nephrotoxic.
Patients who are exposed to nephrotoxic agents may be subjected
to additional insults to the kidney, such as sepsis, hypoperfusion, or
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e2998ischemia and reperfusion. These multiple insults increase the risk for
AKI. AKI is associated with high morbidity and mortality and is a
major economic burden due to the high cost of supportive medical
treatment. The mortality among critically ill patients with AKI
remains high despite increasing ability to support vital organs [14].
Thus, any therapeutic modality conferring resistance to AKI is
anticipated tohave alarge impact on improved survivalofcriticallyill
patients and on public health.
Recombinant SV40 capsids are readily produced in Spodoptera
frugiperda (Sf9) cells using recombinant baculovirus expressing VP1
fromthepolyhedrinpromoter[15,16].VP1spontaneouslyassemble
in the nuclei of infected Sf9 cells forming Virus-Like-Particles
(VLPs). Purified VLPs appear as isolated nanoparticles of uniform
shape and size similar to wild type SV40 virions (Figure S1). Gel
electrophoresis experiments indicate that they contain .95% VP1.
Results
SV40 VLPs upregulate Hsp/c70 and activate Akt-1 in
monkey kidney cells
It was previously demonstrated that SV40 induces Hsc70 15–
20 hours post infection, subsequent to genome entry into the
nucleus [17,18]. It was suggested that Hsc70 induction was a
response to cell proliferation stimulus, presumably via the action of
T-antigen. However, we found (Figure 1A and B) that Hsp/c70
upregulation does not require T-antigen, as it occurs in monkey
kidney CV-1 cells in response to cellular uptake of VLPs alone,
devoid of DNA and T-antigen. Confocal microscopy at 9 hours
following the addition of 50 ng VLPs per 10
6 cells (Figure 1A)
showed increased level of Hsp/c70. Western analysis demonstrates
that Hsp/c70 is upregulated already at 6 hours, with a peak at 12–
24 hours (Figure 1B). Lamin B was used as loading control, since
we found its level to be stable following SV40 or VLP-infection
(unpublished). We further found that VLPs activated Akt-1 via
phosphorylation within 1 hour (compare to mock-infected cells,
Figure 2). Activation of Akt-1 continued for at least 8 hours after
VLP addition. The level of Akt1 protein starts to increase at
3 hours post infection.
Establishment of a pre-clinical model for AKI
The findings described above suggested that if VLPs could
target the kidneys in vivo, they might provide protection against
AKI. We expected the VLPs to target the kidneys, as it is a natural
Figure 1. Upregulation of Hsp/c70 in monkey cultured kidney cells. CV-1 cells were treated with 50 ng VLPs per 10
6 cells, equivalent to moi
of 10 of wild type SV40. (A) Hsp/c-70 analyzed by confocal microscopy at 9 hours post treatment with VLPs. Left-VLP-treated cells; Right–Mock
treated cells. (B) Hsp/c-70 analyzed by Western blotting with monoclonal antibody against Hsp/c70 at the designated time points. HS–heat-shocked
cells serving as a positive control for Hsp70. Lamin B was detected for loading control.
doi:10.1371/journal.pone.0002998.g001
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virus in humans. Confocal microscopy demonstrated extensive
and dense cytoplasmic staining for VLPs with anti-VP1 antibody
in mice kidney sections, following tail-vein injections (Figure 3).
We therefore set to establish an animal model for AKI.
Most animal models of renal failure are not highly reproducible
and poorly represent clinical manifestations of this condition
[19,20]. Following preliminary experiments we chose to use the
mercury intoxication model due to its robustness. Intraperitoneal
injection of HgCl2 to mice led to elevated blood urea in a dose-
dependent manner (Figure S2). For the studies shown below we
selected a dose of 6.5 mg/kg. In our hands, mortality rate at this
dose was ,90% within 7 days.
VLPs protect against mercury-induced cell death in a
tissue-culture model
Before beginning experiments in animals, the hypothesis that
SV40 VLPs may protect against kidney damage was tested in
cultured immortalized mouse tubular cells, MCT, [21], an in vitro
system that best represents the target tissue. Exposure of the cells
to 15 mM HgCl2 led to extensive cell killing, as seen by a large
proportion of rounded, floating cells (Figure 4 left). However,
pretreatment with 50 ng VLPs/10
6 cells, equivalent to an
infection with SV40 at a multiplicity of 10 pfu (plaque forming
units) per cell, provided effective protection (right). Supportive
results were obtained for HEK293 and CV-1 cells (not shown). We
also found that VLPs are capable of cell protection not only
against HgCl2-induced damage, but also against other toxic
agents, such as etoposide (see Figure S3 for HEK293 cells).
In a similar experiment (Figure 5) MCT cells treated with
HgCl2 with and without VLP-pretreatment, were analyzed for the
activation of caspase 9 (as indicated by its autocleavage to 35 kDa)
and activation of caspase 3 (auto-cleaved to 17 kDa fragment).
The results presented in Figure 5 demonstrate that pretreatment
with VLPs abolish the HgCl2-induced activation of both caspases.
Similary, inhibition of caspase 3 activation was also indicated by
elimination of the 89 kDa cleavage product of the apoptotic
protein marker PARP-1.
Pre-treatment with VLPs increases survival of AKI animals
The critical question was whether VLPs are capable of
protecting mice against HgCl2 insult. For the initial studies we
used animal survival as an indication of protection. The design of
the experiments is shown in Figure 6A. Animals were treated in 3
groups: Sham, non treated AKI mice and VLP-treated AKI
animals. VLPs (0.3 mg/kg, in saline) were administered to mice
via the tail vein in 3 consecutive daily injections (0.1 mg/kg each
day, on days -3, -2, -1). Mice that did not receive VLPs were
Figure 2. Activation of Akt-1 by phosphorylation in following VLP-treatment. CV-1 cells treated with 50 ng VLPs per 10
6 cells were
analyzed by Western blotting with anti P-Akt-1 and Akt-1 antibodies. Lamin B –loading control.
doi:10.1371/journal.pone.0002998.g002
Figure 3. VLPs reach the kidneys. VP1 viewed by confocal microsocopy of kidney section harvested from a mouse treated with 0.1 mg/kg VLPs
on 3 subsequent days, total 0.3 mg. VP1 was detected with polyclonal anti-VP1 antibody in renal tissue sections and viewed by confocal microscopy
at magnification x60 and zoom x2 (shown in the inserts). Left–VLP-treated mouse. Middle–Sham mouse. Right-IgG control for non-specific staining by
the secondary Cy5 conjugated antibody. The picture represents a kidney section of a VLP-treated mouse.
doi:10.1371/journal.pone.0002998.g003
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was injected intraperitoneally on the fourth day, which was
counted as day 0, to non-treated and to VLP-treated AKI animals.
Sham animals received intraperitoneal injection of the same
volume of PBS in parallel. Clinical parameters were evaluated on
day 4 and survival was followed until day 14. Pre-treatment with
VLPs resulted in an increase in survival rate from 12% (6/49) to
63% (19/30) (Figure 6B). Statistical analysis using Kaplan-
Meier/ Mantel-Cox log-rank test indicated significance at
P=2 610
26. The hazard rate was 4.04 (95% CI: 2.07–7.91),
meaning that death hazard for a mouse in the non-treated AKI
group was 4.04 times greater than for a mouse in the VLP-treated
group. Furthermore, survival correlated with a milder illness. Most
of the animals in the AKI group were very sick, as seen by
immobility, decreased appetite and alertness, in particular from
day 3 onwards (compare movie S2–a typical AKI animal, to
movie S1–sham animal). In contrast, many of the VLP-treated
AKI animals exhibited only mild to moderate symptoms (movie
S3) and started improving from day 3-4, reaching full recovery
within a week. VLP-treated animals were thus protected from
AKI-related morbidity and mortality. The attenuating effect was
seen over a wide range of doses, from 3 mg/kg to 3 mg/kg
(Figure 6C). Each dose was given in 3 aliquots, following the
same experimental course as above (Figure 6A). The numbers
above the points designate the number of mice tested at the
particular dose. The lower survival rate at the highest VLP dose
that was tested, 30 mg/kg, may be due to toxic effect of the
protein.
Pathological examinations and analyses of clinical
parameters
Representative kidneys of the 3 groups of mice were harvested
on day 4 following the insult (Figure 7). While the AKI kidneys
were small and pale, kidneys from VLP-treated mice appeared
macroscopically similar to sham kidneys. Histopathological
examination of hematoxylin-eosin stained kidney sections (day 4,
Figure 8) showed widespread necrosis of proximal tubular
epithelial cells in the outer cortex (AKI OC). Note absence of
nuclei in necrotic cells (circled tubuli), and shrinkage and
detachment of necrotic epithelial cells from underlying tubular
basement membrane, with ‘tombstone’ appearance (labeled ‘T’).
The arrows point to massive debris in tubular lumen, composed of
cellular fragments and proteinaceous material. In contrast, in
VLP-treated mice apoptosis and necrosis were dramatically
diminished, with only scant necrotic tubular cells, minimal tubular
debris and maintenance of tubular morphology (Figure 8). The
only abnormalities found were occasional tubular dilatation and
irregular large cytoplasmic vacuoles, in particular in the outer
cortex (Figure 8 OC). Apoptosis was assayed by TUNEL
staining, which detects intranuclear DNA damage (negative and
positive controls for TUNEL staining are presented in Figure S4).
Supporting the pathological picture, TUNEL detected extensive
apoptosis of tubular cells of AKI animals (Figure 9, TUNEL
positive nuclei), in particular in proximal convoluted tubuli, while
very few TUNEL positive cells were seen in the VLP-treated
animals (Figure 9, see magnified insert in OC). Notably, there
was no indication that the VLPs induced inflammatory response
during the first 4 days (see hematoxylin-eosin stained sections,
Figure 8).
Serum urea and creatinine, the most commonly used clinical
indices and prognostic indicators of renal function [22,23] were
also tested 4 days post insult. Both were markedly elevated in the
non-treated AKI mice, signifying acute renal failure. This increase
was significantly attenuated in the VLP-treated animals
(Figure 10A and B), with P values 1610
24 for urea and 0.016
Figure 4. VLPs protect against HgCl2 induced death in MCT cells. Left-MCT cells treated by 15 mM HgCl2; Right-MCT cell pretreated with
50 ng/10
6 cells for 4 hours before the addition of 15 mM HgCl2. Images were taken 3 days later. For clarification, both images were identically
adjusted using Adobe Photoshop CS2, by ‘autolevel’ and by increasing brightness (+30).
doi:10.1371/journal.pone.0002998.g004
Figure 5. VLPs prevent activation of caspase 3 and 9 in HgCl2-
treated MCT cells. Western blot analysis of extracts of MCT cell,
treated as designated above. 50 mg of the total protein lysates were
loaded on each lane. The antibodies used for detection are shown on
the left.
doi:10.1371/journal.pone.0002998.g005
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treated with VLPs alone were below detection. While in the non-
treated AKI animals serum urea increased continuously during the
4 days of the experiment, in the VLP-treated AKI mice serum
urea reached a peak on day 3 and decreased thereafter
(Figure 10C). This pattern is compatible with recovery of renal
function and correlated with the higher survival rate of VLP-
treated animals.
Oxidative stress in VLP-treated and non-treated AKI mice
A hallmark of nephrotoxicity is oxidative and nitrosative stress
as evident by overproduction of NO and reactive oxygen species
[24], which most likely lead to tubular cell death [25]. Reactive
hydroxy-free radicals in vivo may be evaluated via the level of lipid
peroxidation, measured as thiobarbituric acid reactive substances
(TBARS) [26]. As seen in Figure 10D, lipid peroxidation was
significantly reduced in VLP-treated mice (P=0.04) at day 4 post
insult. We propose that attenuation of oxidative stress by the VLPs
is part of the process of protection of renal function from mercury-
induced nephrotoxicity.
Activation of renal Akt-1 and upregulation of Hsp/c70 by
VLPs in vivo
The results led us to hypothesize that renal protectionis mediated
via P-Akt-1 and Hsp/c70. We therefore tested whether VLPs
activated both pathways in vivo. For effective protection, both
activities are probably required at the onset of the mercury insult,
day0 inourexperimentalscheme. Mice wereinjected with 0.3 mg/
kg VLPs for 3 consecutive days (as in Figure 6A) and their kidneys
were harvested on the 4th day (day 0). Total kidney proteins were
extracted and analyzed by Western blotting. Figure 11A demon-
strates activation of Akt-1 by serine 473 phosphorylation for all 7
mice tested, while in sham mice phospho-Akt-1 was hardly
detectable. Similar analysis on the same 9 mice (Figure 11B,7
experimental and 2 controls, loaded in a different order) using anti-
Akt-1 antibodies, shows both the phosphorylated and the non
phosphorylated Akt-1 proteins. The level of non-phosphorylated
Akt-1 was almost unchanged. Thus total Akt-1 protein in the VLP-
treated animals was increased, indicating upregulataion.
Evaluation of the bands (Figure 11C) showed that the level of
phospho-Akt-1 was elevated ,15 fold, while total Akt-1 increased
by ,5 fold.
Upregulation of Hsp/c70 was detected by confocal microscopy
of kidney sections. Figure 12 shows a typical staining pattern.
While tubular cells of sham animals showed faint positive
immunostaining for Hsp/c70, the VLP-treated animals had a
markedly higher signal, appearing as a speckled ring around the
nucleus, demonstrating significant upregulation. Non specific
Figure 6. Effect of VLPs on survival rate of AKI mice. (A)
Experimental design. (B) Survival of mice treated with 0.3 mg/kg VLPs
and 6.5 mg/kg HgCl2.( c) Dose response. The number of mice treated at
each VLP dose is shown above. The dose is presented on a logarithmic
scale.
doi:10.1371/journal.pone.0002998.g006
Figure 7. Gross appearance of kidneys. Mice were sacrificed 4 days post HgCl2 administration.
doi:10.1371/journal.pone.0002998.g007
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the IgG control.
Discussion
The present study shows that SV40 VLPs, devoid of DNA,
protect animals from mercury-induced AKI as demonstrated by
attenuation of renal failure, seen by lower serum creatinine and
urea, and by dramatic increase in survival. Tubular cell injury and
apoptosis were almost eliminated. Our results suggest that renal
protection is at least partly achieved by decrease in oxidative stress.
The wide dose range suggests that VLPs are not toxic at the levels
required for kidney protection. Furthermore, there was no
indicationforinflammatoryresponsefollowingVLPadministration.
Our study demonstrates dramatic activation of Akt-1 by VLPs,
with moderate upregulation of the protein. Furthermore, the level
of Hsp/c70 is greatly increased. Notably, the timing of elevation of
Ser 473 Phospho-Akt-1 (the activated species) and Hsp/c70
coincided with the time when animals in the survival study were
given the mercury insult. Furthermore, the immunoblot analysis of
Akt-1 and confocal microscopy of Hsp/c70 of additional animals
suggest that variation in the degree of activation between the
Figure 8. Kidney pathology at 4 days post HgCl2 administration. Sections of renal tissue stained with hematoxylin & eosin
(magnificationX20). OC–outer cortex, IC–inner cortex. Note intratubular debris containing remnants of damaged tubular epithelial cells (arrows).
Circles encompass tubuli lined by necrotic epithelial cells. Note lack of nuclei, granular eosinophilic cytoplasm and preserved cellular outline –
‘tombstone‘ (T). As pictures were taken under variable lighting conditions, they were enhanced using ‘auto levels’ adjustment, Photoshop CS2 for
Macintosh.
doi:10.1371/journal.pone.0002998.g008
Figure 9. Detection of apoptosis in kidney sections. TUNEL assay was performed 4 days post HgCl2-treatment. Slides were photographed at
x60 and Zoom 2 (see inserts). For positive and negative controls for the TUNEL assay see Figure S4.
doi:10.1371/journal.pone.0002998.g009
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VLPs against AKI is based on activation of both pathways leading
to survival. Chaperons were recently implicated in renal protection
against AKI [7,8,9,10]. Akt-1 is a key player in activation of
survival pathway, leading to apoptosis arrest [27,28]. Akt-1 was
also shown to diminish oxidative stress [29]. Our experiments in
cultured mouse tubular cells indicate that part of the apoptotic
arrest is mediated via the inhibition of capspase 9 and caspase 3.
Figure 10. Serum indices: Serum urea level (A) and serum creatinine (B) 4 days following HgCl2 administration. S–sham mice; V–control mice
treated with VLPs; A–AKI mice; A+V–AKI mice treated with VLPs. The number of mice in each column is depicted below. (C) Urea level measured at
several time points after HgCl2 administration (at day 0). The number of mice in each group was: Sham–4 mice; AKI–9 mice; AKI+VLP–9 mice. (D)
TBARS assays were performed 4 days post HgCl2 administration.
doi:10.1371/journal.pone.0002998.g010
Figure 11. Activation of Akt-1 by VLPs in the kidney. (A) Ser 473 phosphorylated Akt-1 detected by anti-P-Akt antibody. (B) Detection of total
Akt-1 by Akt-1 antibody. Total soluble proteins (10 mg for P-Akt-1 and 250 mg for total Akt-1) extracted from kidneys of 2 sham mice and 7 VLP-
treated mice were loaded on each lane. The numbers above designate specific Sham and VLP-treated mice. (C) The levels of P-Akt-1 and Akt-1 in VLP-
treated (V-7 mice)) and sham (S-2 mice). Evaluation was performed by TotalLab software.
doi:10.1371/journal.pone.0002998.g011
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Israeli and Oppenheim, unpublished), using proteomics arrays,
have indicated that VLPs activate PLCc. Using specific inhibitors
we found that Akt-1 activation fully depends on PLC-signaling,
and only partly on PI3K. Activation of Akt-1 by phosphrylation at
serine 473 was shown to lead to survival pathway [30] via
regulation of proapoptotic proteins such as Bad, caspase 9 and p53
[28]. Furthermore, a number of publications showed that
activation of PLC-PI3K-AKT signaling led to apoptosis arrest in
neurodegeneration [31] and atherosclerosis [32]. We propose that
a similar pathway is induced by the SV40 VLPs in the kidney. Our
unpublished studies further indicate that PLCc signaling leads to
upregulation of Hsp/c70. Induction of Hsp/c70 might proceed via
PLC dependent PKC activation as previously described for a heat
stress model [33].
Chaperones play a role in SV40 disassembly [34]. Here we
show that the infecting virus induces chaperone upregulation via
signals triggered by its coat proteins, very early post infection.
Taken together, these findings suggest that upregulation of cellular
chaperone may be part of the signaling program that functions in
viral entry and disassembly.
We have asked whether VLPs may also have a therapeutic effect
for animals with AKI. The experiments indicated that adminis-
tration of VLPs following the HgCl2 insult did not lead to
increased survival. This is most likely because of the time required
for the induction of the Akt survival pathway and chaperone
upregulation. Thus, the VLPs do not appear to lead to kidney
regeneration, but rather to prevention of injury.
A critical limitation in treating human patients with a foreign
protein such as SV40 VLPs is the risk of developing immune
response, which would preclude repeated administrations. We and
others found that SV40 vectors used for gene delivery in mice did
not elicit neither cellular immune response [35] nor humoral
immune response [35,36]. This may be partly due to the unique
mode of entry of SV40 via caveolae and the ER, bypassing the
endosomal pathway [3]. In addition, we found that SV40 activates
FLIP, via phosphorylation, following infection of tissue-cultured
cells. FLIP was demonstrated to suppresses downstream signals
from T killer cells [37] and could therefore also partly account for
non-immunogenicity of SV40 vectors. The early activation of
FLIP (within one hour of SV40 infection, long before the viral
genome enters the nucleus and starts transcribing) suggests that it
would also be induced by VLPs. We therefore anticipate that like
SV40 vectors, VLPs might also be non-immunogenic, allowing
repeated treatments. Of note, FLIP activation by SV40 may be
another anti-apoptotic renal protective mechanism, in addition to
AKT activation and Hsp70 upregulation.
In this proof-of-principle therapeutic study we showed that VLP
administration conferred protection against HgCl2-induced AKI,
presumably via activation of the Akt-1 survival pathway and
chaperones. Production of VLPs is a simple, low cost procedure,
and the absence of genetic material circumvents inherent risks of
gene therapy. Thus this strategy may potentially be developed as a
preventative medical measure against AKI.
VLPs protected human HEK293 and monkey CV-1 cells also
against etoposide-induced apoptosis, suggesting wide range
applicability of VLPs for cell and tissue survival. SV40-based
vectors were shown to reach many targets in vivo [38,39,40].
Numerous reports suggest that Akt survival pathway and
chaperones are involved in many types of organ failure, not just
the kidney. Thus the findings described here may be extended to
additional clinical conditions. Furthermore, viruses have evolved
to enter cells by a variety of mechanisms, inducing a wide array of
cellular responses. One may predict that virus-induced host
signaling would by applicable as novel medical modalities to a
large spectrum of diseases.
Materials and Methods
Cell cultures and media
Spodoptera frugiperda (Sf9) cells were grown at 27uC in serum-free
Bio-insect medium containing glutamine, penicillin, streptomycin
and amphotericin (Biological Industries, Israel). African Green
monkey CV-1 cells (ATCC # CCL-70), Human Embryonic
Kidney 293 cells (ATCC #CRL-1573) and Mouse Tubular cells
[21] were cultured in high glucose Dulbecco’s modified Eagle’s
medium containing glutamine, penicillin, streptomycin, and 10%
FBS.
Production and purification of VLPs
Recombinant baculovirus expressing VP1 (Swiss-Prot P03087,
PDB 1SVA) from the polyhedrin promoter were used for
production of VLPs as previously described [15]. VLPs were
purified by either of two methods, as described below. Both
methods gave essentially the same results.
In the first set of experiments we used a method developed for
assembly of VP1 around DNA, except that DNA was omitted
from the assembly reaction [41]. VP1 was isolated from nuclear
extracts of Sf9 cells, containing 1–3 mg VP1/ml nuclear extract.
The VLPs were purified and concentrated by stirred-ultrafiltration
under Argon using XM300 membrane (Millipore). They were
stored in 0.5 N NaCl and diluted to isotonic ionic strength
immediately before use.
In later experiments the VLPs were harvested from the medium
of baculovirus-infected Sf9 following cell lysis, 5 days post
Figure 12. Upregulation of Hspc/70. Hsp/c70 viewed by confocal microscopy at magnification x60 and zoom x2. Left–VLP-treated mice. Right–
Sham mice. IgG-negative control. For clarification, both images were identically adjusted using Adobe Photoshop CS2, by ‘autocolor’ adjustment.
doi:10.1371/journal.pone.0002998.g012
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centrifugations at 6,000xg for 10 min. The supernatant was
further clarified at 17,000xg for 20 min. VLPs were precipitated at
80,000xg, 3 hrs. The VLP pellet was suspended in 0.5 M NaCl,
purified by ultrafiltration and stored as above. As stated above
both methods of preparation gave essentially the same results.
Total protein was determined by the Bradford assay. The
amount and purity of VP1 in each VLP preparation was estimated
by SDS-PAGE and staining with Coomassie or Silver Stain. Both
staining methods gave similar results.
Animal studies
Balb/C female mice, 8–10 weeks, 19–21 gm, were kept in a SPF
unit in the animal facility at the Hebrew University Medical
School. VLPs were injected via the tail vein in a total volume of
0.1 ml. HgCl2 was injected intraperitoneally in a total volume of
0.4 ml. Mice were sacrificed at the indicated times humanely via
cervical dislocation under deep anesthesia. Animal care and
experiments were conducted in accordance with the Hebrew
University-Hadassah Animal Authority guidelines.
Serum tests
Serum urea and creatinine were measured using Reflotron
sticks (Roche). TBARS assay was performed according to the
protocol of Animal Models of Diabetic Complications Consortium
(AMDCC; www.amdcc.org/shared/Protocols.aspx).
Protein expression studies
Cultured cells: VLPs were added to subconfluent cells, in a small
volume of serum-free medium, grown in 25 cm
2 tissue-culture bottles
(for total protein extraction and Western analyses) or on microscopic
cover slips (for phase and confocal microscopy). 50 ng VLPs were
added per 10
6 cells, approximately equivalent to multiplicity of
infection (moi) of 10 plaque forming units (pfu) of SV40 per cell.
(Molecular weight of a VP1capsid is ,15 MDa, thus 50 ng represent
2610
9 capsids. Not more than 1 of 200 particles in SV40 stocks are
infectious [42] (and our unpublished data), 2610
9 SV40 virions
contain 1610
7 pfu, or moi 10 per when applied to 10
6 cells.
The VLPs were allowed to adsorb to the cells in the cold on a
gyratory shaker, at 20 rpm. Medium was added and the cells were
transferred for incubation at 37uC. Total protein extracts were
prepared by lysing the cells in 0.6% SDS in 10 mM Tris pH-7.4
buffer. Samples containing 50 mg protein were loaded on each
lane. Hsp/c70 was detected by confocal microscopy in cells fixed
in 4% formaldehyde.
Mice kidneys: Proteins were extracted from frozen mouse
kidneys using RIPA [43] For microscopy, kidneys were fixed in
4% formaldehyde. Paraffin-embedded kidney sections were
dewaxed, rehydrated and stained.
Antibodies
The following antibodies were used: Akt-1, polyclonal; P-Akt-1,
polyclonal against phosphorylated S473; Caspase 9, monoclonal;
Caspase 3 polyclonal (Cell Signaling). Hsp/c70, monoclonal (clone
BB70 Stressgen); PARP-1, polyclonal antibody (Alexis). Lamin B,
polyclonal antibody (Santa Cruz). VP1, polyclonal antibody
prepared in our laboratory [15]. For confocal microscopy we used
Cy5 as secondary antibody. Controls for confocal microscopy
included sections without any staining, sections stained with
secondary antibody only, and sections obtained from sham animals.
TUNEL detection
DNA strands breaks detected by TUNEL, using In Situ Cell
Death Detection kit, and fluorescien (Roche), following manufac-
turer protocol. Briefly, paraffin-embedded kidney sections har-
vested on day 4 were dewaxed, rehydrated and protease-treated
(10 mg/ml proteinase K, Roche), followed by permeabilization by
Tritone X-100, labeling with terminal transferase and detection by
confocal microscopy. Negative control slides were incubated with
the same labeling solution without terminal transferase. Positive
control slides were prepared by adding DNAse I (5 u/ml) for 1 hr
at room temperature after permeabilisation.
Statistical analysis
Survival data were analyzed statistically using the Kaplan-Meier
procedure, and the Mantel-Cox log-rank test was applied for
comparing survival curves between study groups. Quantitative
clinical indices were analyzed by comparing the VLP-treated and
untreated AKI groups using Student’s independent t-test (two-
tailed). A P-value of 5% or less was considered statistically
significant.
Supporting Information
Figure S1 Structure of the VLPs. Transmission electron
microscopy pictures of VLPs and wild type SV40. Samples,
adsorbed onto UV-irradiated formovar-carbon-coated copper
grids and stained with 1% uranyl acetate. The samples were
viewed in a Philips CM-12 electron microscope, using a voltage of
100 kV, and photographed at x53,000. The bars represent 50 nm.
Found at: doi:10.1371/journal.pone.0002998.s001 (1.96 MB TIF)
Figure S2 Nephrotoxic mouse model for AKI. HgCl2 was
injected intraperitoneally (on day 0) in a total volume of ,0.4 ml
to 9–10 weeks old female Balb/c mice. Average weight ,20 gr.
Blood was withdrawn from the tail vein and urea level was
measure in the serum.
Found at: doi:10.1371/journal.pone.0002998.s002 (2.35 MB
DOC)
Figure S3 Protection of HEK293 from etoposide-induced
apoptosis by VLPs. 50 mM etoposide was added to HEK293fol-
lowing pretreatment with 50 ng/106 cells VLPs for 4 hours.
Images were taken 3 days later.
Found at: doi:10.1371/journal.pone.0002998.s003 (4.24 MB TIF)
Figure S4 Controls for TUNEL staining. (A). Negative controls:
Mouse tissue was treated as for TUNEL staining but without
terminal transferase. (B). Positive controls: Following permeabili-
zation with Tritone X-100 the slides were treated with DNase I,
then incubated with the complete labeling solution.
Found at: doi:10.1371/journal.pone.0002998.s004 (9.93 MB TIF)
Movie S1 Sham mouse
Found at: doi:10.1371/journal.pone.0002998.s005 (6.83 MB
MOV)
Movie S2 AKI mouse
Found at: doi:10.1371/journal.pone.0002998.s006 (8.84 MB
MOV)
Movie S3 VLP-treated AKI mouse
Found at: doi:10.1371/journal.pone.0002998.s007 (5.34 MB
MOV)
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